BOSTON, April 9, 2025 -- Solu Therapeutics, a biotechnology company pioneering therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced the successful completion of a $41 million Series...
Arthur Klausner will be a panelist at "The Venture Prognosis - what's driving investment preferences?" at the Life Sciences & Healthcare Venture Summit on October 23, 2007 in NYC
News | 10. 23. 2007
